Recent Press Releases

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties

The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock,...

AstraZeneca Announces Plans to Expand its Frederick, Maryland Biologics Manufacturing Center

$200+ Million Investment to Support Company's Maturing Biologics Pipeline FREDERICK, Md.--(BUSINESS WIRE)--AstraZeneca today announced plans to expand its biologics manufacturing center in...

European CHMP Adopts Positive Opinion for Genzyme's Cerdelga® (eliglustat) Capsules

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genzyme, a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...

No consistent evidence of an increased risk of heart problems with testosterone medicines

European Medicines Agency - The CMDh, a regulatory body representing EU Member States, has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with...

Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

• Phase III INPULSIS® trials showed that nintedanib* slows disease progression in a broad range of IPF patient types** with a 50% reduction in the decline of lung function •...

Spherix Comments on Pending Settlement Between Cisco and Rockstar Consortium

Spherix Litigation Against Cisco Continues On Patents Acquired from Rockstar Consortium

BETHESDA, Md., Nov.

Purdue Pharma L.P. Receives FDA Approval for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties

Purdue Pharma L.P. Receives FDA Approval for HysinglaTM ER (hydrocodone bitartrate) Extended-Release Tablets CII, A Once-Daily Opioid Analgesic Formulated with Abuse-Deterrent Properties Stamford,...

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties

FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties For Immediate Release: Nov. 20, 2014 Media Inquiries: Jeff Ventura, 301-796-7567,...

IMS Health Study Forecasts Global Spending on Medicines to Increase 30 Percent by 2018, to $1.3 Trillion

Spike in Growth in 2014-15 Driven by Innovation Surge and Few Patent Expiries PARSIPPANY, NJ, November 20, 2014 – More specialty drug innovation, greater patient access to medicines and reduced...

Janssen Submits New Drug Application to U.S. FDA for Three-Month Paliperidone Palmitate

First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults

TITUSVILLE, N.J., Nov.

Shire to Relocate Over 500 Jobs to Massachusetts

Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases Presence in Chesterbrook, Pa. Interim CFO Appointed Lexington, Mass., November 19, 2014 – Shire plc (LSE: SHP,...

Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

American Heart Association's Scientific Sessions 2014: Latest real-world data once again reinforce benefits from Pradaxa®1,2 Two new analyses involving over 60,000 US patients in total...

New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

Idarucizumab, which was granted Breakthrough Therapy Designation by the FDA, was shown to restore the blood clotting mechanism in healthy volunteers1,2 This is the first time that such an effect...

Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels

Additional Data Analysis Showed Every Two Week and Monthly Dosing Regimens of Evolocumab Were Clinically Equivalent

THOUSAND OAKS, Calif.

Zoetis Announces Authorization of $500 Million Share Repurchase Program

Zoetis Announces Authorization of $500 Million Share Repurchase Program FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Zoetis Inc.(ZTS), the world's leading animal health company, today announced that its...

European Commission Grants Marketing Authorization for Gilead's Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

-- Once-Daily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis -- FOSTER CITY,...

ASTRAZENECA STRATEGY ON TRACK TO DELIVER SUSTAINABLE GROWTH AND VALUE THROUGH INNOVATION

Late-stage pipeline transformed well ahead of plan through increased R&D productivity, accelerated programmes and targeted business development; 14 potential new medicines in Phase III or...